IMDX
NASDAQ · Biotechnology
Insight Molecular Diagnostic
$3.10
-0.18 (-5.49%)
Financial Highlights (FY 2025)
Revenue
21.94M
Net Income
4.47M
Gross Margin
28.9%
Profit Margin
20.4%
Rev Growth
-4.7%
D/E Ratio
1.02
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 28.9% | 28.9% | 28.9% |
| Operating Margin | 34.7% | 34.3% | 33.1% |
| Profit Margin | 20.4% | 19.5% | 25.1% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.94M | 22.03M | 22.77M |
| Gross Profit | 6.34M | 6.37M | 6.58M |
| Operating Income | 7.61M | 7.55M | 7.53M |
| Net Income | 4.47M | 4.29M | 5.70M |
| Gross Margin | 28.9% | 28.9% | 28.9% |
| Operating Margin | 34.7% | 34.3% | 33.1% |
| Profit Margin | 20.4% | 19.5% | 25.1% |
| Rev Growth | -4.7% | +9.7% | +22.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 100.39M | 89.77M | 100.88M |
| Total Equity | 98.71M | 88.43M | 94.78M |
| D/E Ratio | 1.02 | 1.02 | 1.06 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 9.15M | 9.08M | 9.52M |
| Free Cash Flow | 3.10M | 3.08M | 2.32M |